AlphAIAlphAI — Financial news for AI agents
GlobeNewswireNOV 283 min read$KTTA

Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock

MIAMI, Nov. 28, 2025 ( GLOBE NEWSWIRE ) -- Pasithea Therapeutics Corp. ( "Pasithea" or the "Company" ) ( Nasdaq: KTTA. KTTAW ) , a clinical-stage biotechnology company developing PAS-004, a next-generation macrocyclic oral MEK inhibitor for the treatment of neurofibromatosis type 1-associated ...

Original reporting
GlobeNewswire · Pasithea
Published Nov 28, 2025, 2:20 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 28, 2025, 2:31 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Pasithea Therapeutics Announces Pricing of $60 Million Public Offering of Common Stock — source image
Source · www.globenewswire.com
Decision brief

The 30-second read

$KTTANeutralLow
01

Why it matters

The public offering aims to fund ongoing clinical trials and expansion efforts. Market response is cautious, reflecting typical dilution effects.

02

Market read

Limited immediate trading impact; primarily relevant for biotech investors and stakeholders.

03

What to watch

Market may interpret the offering as a sign of confidence and future growth prospects, offsetting dilution concerns.

Relevance 6/10Timing: short-term

Background

Pasithea Therapeutics is a clinical-stage biotech developing neurofibromatosis treatments, with recent focus on PAS-004, a macrocyclic MEK inhibitor.

Company-level read

Ticker impact

$KTTANeutralMedium confidence
Context

Primary focus due to recent public offering and potential impact on stock valuation.

Expected impact

Minimal short-term fluctuation; potential slight downward pressure due to dilution, but offset by capital infusion.

Evidence & confidence

The offering size is moderate relative to the company's valuation, and market sentiment remains neutral. No significant technical signals or industry shifts are evident.

Market effects

Sector

Biotech sector may experience slight investor caution due to capital raising activities.

Regional

Limited regional impact; primarily affects US biotech stocks.

Global

Low; specific to company and sector.

Counterpoint

What could challenge this read

The capital infusion could enable Pasithea to accelerate development, potentially leading to positive long-term valuation adjustments.

Key entities

  • Company
    Pasithea Therapeutics

    Biotech firm specializing in neurofibromatosis treatments.

Read at source← All news

Related articles

OCT 23
$KTTAMedAI 8/10

Two people with advanced cancer remain on a trial drug for over 500 days, with stable disease.

Pasithea Therapeutics (KTTA) reported positive data from its Phase 1 trial of PAS-004, showing prolonged stable disease in four advanced cancer patients, including two on treatment for over 500 days. The drug demonstrated a favorable safety profile with no serious adverse events and a long half-life supporting chronic dosing. Data was presented at ESMO Congress 2026.

stocktitan.net2 min
JUN 2
$KTTAMedAI 9/10

Pasithea's PAS-004 Receives FDA Orphan Drug Designation In Treating AL. Sclerosis

Pasithea Therapeutics (KTTA) said the U.S. FDA granted Orphan Drug Designation to PAS-004 for amyotrophic lateral sclerosis (ALS). The company said PAS-004 is a macrocyclic MEK inhibitor and is in Phase 1 trials in advanced cancer and Phase 1/1b trials in NF1-associated plexiform neurofibromas. Orphan status can bring tax credits, fee exemptions, and up to seven years’ exclusivity after approval.

rttnews.com3 min
OCT 23
$BMYMed

Bristol Myers Squibb Reports CAR T-Cell Therapy Data In Multiple Sclerosis

Bristol Myers Squibb (BMY) reported interim Phase 1 Breakfree-2 study results for its CAR T-cell therapy zolacabtagene autoleucel in 66 multiple sclerosis patients. 92% of progressive MS patients showed stable or improved disability. Safety issues included cytokine release syndrome in 42.4% of patients. BMY stock is down 2.26% at $61.56.

rttnews.com2 min